Axoft Raises $55M Oversubscribed Series A
Neurotech startup Axoft secures an oversubscribed $55 million Series A to fast-track clinical trials and FDA clearance of its revolutionary Fleuron™.
Axoft
Neurotech startup Axoft secures an oversubscribed $55 million Series A to fast-track clinical trials and FDA clearance of its revolutionary Fleuron™.